Trial reportThe Journal of urology2010
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Trial report in The Journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 121 citations in OpenAlex.
- Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.The Journal of urology · 2012Trial
- Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.The Journal of urology · 2011Trial
- Drug-Induced Osteoporosis.Journal of clinical medicine · 2026Review
- Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.Cancer medicine · 2025Review
- Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.Diseases (Basel, Switzerland) · 2025Review
- Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.Journal of bone and mineral metabolism · 2023Review
- Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.The world journal of men's health · 2020Review
- A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin.Medicina (Kaunas, Lithuania) · 2019Article
- The skeletal impact of cancer therapies.British journal of clinical pharmacology · 2019Review
- Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.Asia-Pacific journal of clinical oncology · 2019Review
- Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.British journal of cancer · 2019Article
- Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects.Journal of the Endocrine Society · 2018Article
- Cancer Treatment and Bone Health.Calcified tissue international · 2018Review
- Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment.Frontiers in endocrinology · 2018Review
- Adverse bone effects of medications used to treat non-skeletal disorders.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Review
- Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Physiological reviews · 2017Review
- Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Journal of endocrinological investigation · 2016Article
- Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.Clinical & experimental metastasis · 2016Article
- Which play a more important role in the development of large-sized prostates (≥80 ml), androgen receptors or oestrogen receptors? A comparative study.International urology and nephrology · 2016Article
- Antiresorptive therapy in the management of cancer treatment-induced bone loss.Current osteoporosis reports · 2015Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeAndrogen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period. MATERIALS AND
methodsIn this double-blind, placebo controlled phase III study 646 men receiving androgen deprivation therapy for prostate cancer were assigned to toremifene (80 mg by mouth daily) and 638 were assigned to placebo. Subjects were followed for 2 years. The primary study end point was new vertebral fractures. Secondary end points included fragility fractures, bone mineral density and lipid changes.
resultsThe 2-year incidence of new vertebral fractures was 4.9% in the placebo group vs 2.5% in the toremifene group, a significant relative risk reduction of 50% (95% CI -1.5 to 75.0, p = 0.05). Toremifene significantly increased bone mineral density at the lumbar spine, hip and femoral neck vs placebo (p <0.0001 for all comparisons). There was a concomitant decrease in markers of bone turnover (p <0.05 for all comparisons). Toremifene also significantly improved lipid profiles. Venous thromboembolic events occurred more frequently with toremifene than placebo with 7 subjects (1.1%) in the placebo group experiencing a venous thromboembolic event vs 17 (2.6%) in the toremifene group. Other adverse events were similar between the groups.
conclusionsToremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.